220 related articles for article (PubMed ID: 32786396)
1. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
2. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
3. Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.
Longhi MS; Feng L; Robson SC
Biochem Pharmacol; 2021 May; 187():114417. PubMed ID: 33460629
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.
Zhong EH; Ledderose C; De Andrade Mello P; Enjyoji K; Lunderberg JM; Junger W; Robson SC
Am J Physiol Cell Physiol; 2021 Jan; 320(1):C15-C29. PubMed ID: 33052071
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
6. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
8. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
Geoghegan JC; Diedrich G; Lu X; Rosenthal K; Sachsenmeier KF; Wu H; Dall'Acqua WF; Damschroder MM
MAbs; 2016; 8(3):454-67. PubMed ID: 26854859
[TBL] [Abstract][Full Text] [Related]
10. Human platelets express functional ectonucleotidases that restrict platelet activation signaling.
Chaurasia SN; Kushwaha G; Pandey A; Dash D
Biochem Biophys Res Commun; 2020 Jun; 527(1):104-109. PubMed ID: 32446352
[TBL] [Abstract][Full Text] [Related]
11. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors.
Schäkel L; Mirza S; Pietsch M; Lee SY; Keuler T; Sylvester K; Pelletier J; Sévigny J; Pillaiyar T; Namasivayam V; Gütschow M; Müller CE
Arch Pharm (Weinheim); 2021 Dec; 354(12):e2100300. PubMed ID: 34697820
[TBL] [Abstract][Full Text] [Related]
12. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
14. Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39.
Goueli SA; Hsiao K
PLoS One; 2019; 14(10):e0220094. PubMed ID: 31652269
[TBL] [Abstract][Full Text] [Related]
15. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
16. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
17. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
19. The Inhibition of CD39 and CD73 Cell Surface Ectonucleotidases by Small Molecular Inhibitors Enhances the Mobilization of Bone Marrow Residing Stem Cells by Decreasing the Extracellular Level of Adenosine.
Adamiak M; Bujko K; Brzezniakiewicz-Janus K; Kucia M; Ratajczak J; Ratajczak MZ
Stem Cell Rev Rep; 2019 Dec; 15(6):892-899. PubMed ID: 31520298
[TBL] [Abstract][Full Text] [Related]
20. Ectonucleotidases in Intestinal and Hepatic Inflammation.
Vuerich M; Robson SC; Longhi MS
Front Immunol; 2019; 10():507. PubMed ID: 30941139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
